Previous 10 | Next 10 |
Although Neurocrine Biosciences ( NBIX ) has a strong primary commercial asset in Ingrezza, a slower-building but still promising secondary asset partnered to AbbVie ( ABBV ) in Orlissa, and an improved pipeline, the reality is that the shares of biotechs in Neurocrine’s stage of li...
Voyager’s vectorized antibody program directed against tau demonstrates antibody distribution and expression levels in specific cell types that further facilitate studies with a vectorized antibody in animal models of disease New TRACER™ system enables the rapid discover...
Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...
In February I wrote about Axovant Gene Therapies Ltd ( AXGT ), formerly Axovant Sciences ( AXON-OLD ), providing my thoughts on data expected in March 2019 from two of the company's trials, one in Parkinson's disease and one in GM2 gangliosidosis. I believed it was too early to recommend a l...
Novartis's 8.7 billion bet Last year Novartis ( NVS ) made waves by acquiring the gene therapy company AveXis for an astounding 8.7 billion dollars , setting in motion a rush of additional buyouts in this therapeutic space including Spark Therapeutics (4.8 billion) and Nightstar Therapeu...
CAMBRIDGE, Mass., April 15, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced multiple data presentations at the American Society of Gene ...
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, granted restricted stock units and a non-qualified stock option to Robert He...
CAMBRIDGE, Mass., April 02, 2019 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases today announced management’s presentation at the upcoming investor con...
SAN DIEGO and CAMBRIDGE, Mass., March 28, 2019 (GLOBE NEWSWIRE) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Voyager Therapeutics, Inc. (NASDAQ: VYGR) today announced the publication of interim results from the Phase 1b trial of VY-AADC, an investigational gene therapy treatment for P...
News, Short Squeeze, Breakout and More Instantly...
Voyager Therapeutics Inc. Company Name:
VYGR Stock Symbol:
NASDAQ Market:
Voyager Therapeutics Inc. Website:
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in fireside chats at the TD Cowen Genetic Medicines & RNA Summit on June 20, ...
LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgense...
LEXINGTON, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the first participants were dosed in a Phase 1a single ascending dose (SAD) trial of VY-TAU01, an investigation...